The market charged ahead in October after retreating for two months, with the Dow industrials advancing 8.5%. Encouraging signals from central banks and better-than-expected earnings, especially from tech companies, got much of the credit for the rally.

But one highflying pharmaceutical stock fell hard, and money managers showed signs of being...